ENGINEERINGNET.EU -- Roch Doliveux, CEO of UCB during the ceremony: "The decision to add biotechnology manufacturing capability is significant for UCB, especially since this new plant – along with the Braine l’Alleud site in Belgium - is destined to become a strategic biotechnological production centre for the group."
With an estimated total investment of up to €250 million, the new production unit will focus on producing UCB’s antibody-based drugs, including Cimzia (certolizumab pegol), which treats the symptoms of Crohn’s disease and rheumatoid arthritis.
The investment should ultimately lead to the creation of up to approximately 140 new jobs.
BACKGROUND
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011.
